Re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole Time Director of the Company for another term of 5 years effective from April 01, 2027, subject to the approval of ....
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong FY26 results with consolidated profit after tax rising 29.6% to ₹1,736 million from ₹1,340 million in FY25. Total income grew 16.5% to ₹7,806 million. The Board recommended a final dividend of ₹1.35 per share (67.5% on ₹2 face value) for FY25-26, payable after shareholder approval at the 37th AGM. The Board also decided to defer an interim dividend to preserve capital for potential strategic opportunities. Key leadership continuity was confirmed with the approval of Mr. Mukund Kabra's re-appointment as Whole-Time Director for another 5-year term from April 2027, and the appointment of Mr. Pradip Bhailal Shah as an Independent Director for 5 years from June 2026. Additionally, 49,350 equity shares were allotted under the ESOP 2022 scheme.
The strong profit growth and dividend recommendation are positive signals for shareholders. The re-appointment of Mr. Kabra provides leadership continuity. The decision to preserve capital for strategic purposes suggests the company may pursue acquisitions or expansions.